Humira's extensive patent portfolio, often referred to as a "patent thicket," has been a key strategy to extend market exclusivity beyond the initial patent expiry. This approach involves securing numerous patents covering various aspects of the drug, such as its formulation, method of use, manufacturing process, and even specific patient populations.
How many patents protect Humira?
Humira is protected by a large number of patents. While the exact number fluctuates due to new filings and expirations, reports indicate that AbbVie, the manufacturer of Humira, has secured over 100 patents related to the drug [1]. This extensive patenting strategy is designed to create a complex legal landscape for potential competitors.
Why are companies challenging Humira's patents?
Companies seeking to launch biosimilar versions of Humira actively challenge its patents to gain market access. These challenges are often part of litigation aimed at invalidating patents that they believe are weak, expired, or were improperly granted. For example, Amgen has been involved in patent litigation regarding Humira [2].
When does Humira's market exclusivity end?
The primary patents protecting Humira have expired or are expiring, paving the way for biosimilar competition. However, the patent thicket has created a staggered timeline for when biosimilars can actually launch. In the United States, major biosimilar launches began in 2023 after resolving patent disputes [1][3]. Exclusivity timelines can vary by region.
What are the implications of Humira's patent thicket for biosimilars?
The patent thicket has significantly delayed the entry of biosimilars in some markets. Competitors must navigate and challenge multiple patents, a process that can be lengthy and costly. This strategy has successfully extended Humira's market dominance beyond what might be expected with a single core patent [1].
How do Humira biosimilars compare to the reference drug?
Biosimilar versions of Humira are designed to be highly similar to the reference biologic drug in terms of safety, purity, and potency. They are approved for the same indications as Humira. For example, biosimilars approved in the U.S. target conditions like rheumatoid arthritis, psoriatic arthritis, and Crohn's disease [3].
Who are the major competitors developing Humira biosimilars?
Several pharmaceutical companies have developed and launched or are preparing to launch biosimilars of Humira. These include Amgen, Sandoz, Boehringer Ingelheim, and Pfizer, among others [2][3]. The market entry of these biosimilars is expected to increase competition and potentially lower drug costs.
What is the expected impact of biosimilar competition on Humira's sales?
The introduction of biosimilars is anticipated to significantly reduce Humira's market share and sales. This is a common pattern observed with the entry of biosimilars for highly successful biologic drugs.
Sources:
1. DrugPatentWatch.com
2. Amgen
3. U.S. Food & Drug Administration